Leavitt Partners December 1, 2022
Kristin Allen

Leavitt Partners examined publicly available resources to determine the 340B Drug Pricing Program’s (340B) impact on drug prices charged by both covered entities and pharmaceutical manufacturers. To answer these questions, Leavitt Partners undertook a comprehensive literature review of publicly available governmental reports, peer-reviewed journal articles, white papers, news articles, and other publicly available sources to identify the degree to which, and to what...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Healthcare System, HHS, Insurance, Medicare, Pharma, Pharma / Biotech, Pricing / Spending, Provider, Survey / Study, Trends
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies
CAR T-Cell Pioneer Plots Technology’s Next Steps
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services
GLP-1 drug use for weight loss has soared, costing billions

Share This Article